- Home
- ECPG vs IMNM Comparison
ECPG vs IMNM Comparison
Compare ECPG & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECPG
- IMNM
- Stock Information
- Founded
- ECPG 1998
- IMNM 2006
- Country
- ECPG United States
- IMNM United States
- Employees
- ECPG N/A
- IMNM N/A
- Industry
- ECPG Finance Companies
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- ECPG Finance
- IMNM Health Care
- Exchange
- ECPG Nasdaq
- IMNM Nasdaq
- Market Cap
- ECPG 806.1M
- IMNM 748.3M
- IPO Year
- ECPG 1999
- IMNM 2020
- Fundamental
- Price
- ECPG $37.83
- IMNM $8.75
- Analyst Decision
- ECPG Strong Buy
- IMNM Strong Buy
- Analyst Count
- ECPG 3
- IMNM 5
- Target Price
- ECPG $62.67
- IMNM $26.40
- AVG Volume (30 Days)
- ECPG 335.7K
- IMNM 973.9K
- Earning Date
- ECPG 05-07-2025
- IMNM 05-12-2025
- Dividend Yield
- ECPG N/A
- IMNM N/A
- EPS Growth
- ECPG N/A
- IMNM N/A
- EPS
- ECPG N/A
- IMNM N/A
- Revenue
- ECPG $1,380,750,000.00
- IMNM $10,938,000.00
- Revenue This Year
- ECPG $21.70
- IMNM N/A
- Revenue Next Year
- ECPG $8.86
- IMNM $542.22
- P/E Ratio
- ECPG N/A
- IMNM N/A
- Revenue Growth
- ECPG 11.49
- IMNM N/A
- 52 Week Low
- ECPG $26.45
- IMNM $5.15
- 52 Week High
- ECPG $51.77
- IMNM $16.81
- Technical
- Relative Strength Index (RSI)
- ECPG 49.06
- IMNM 58.92
- Support Level
- ECPG $37.16
- IMNM $8.50
- Resistance Level
- ECPG $39.16
- IMNM $9.04
- Average True Range (ATR)
- ECPG 0.94
- IMNM 0.53
- MACD
- ECPG -0.39
- IMNM 0.07
- Stochastic Oscillator
- ECPG 3.31
- IMNM 76.16
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.